Traditional Chinese Herbal Formula Shows Superior Kidney Function Preservation in Diabetic Kidney Disease Trial
Key Insights
A 24-week randomized clinical trial of 120 patients found that a traditional Chinese herbal formula (search) significantly improved kidney function markers compared to standard irbesartan therapy in diabetic kidney disease (search).
While both treatments achieved similar reductions in urinary protein levels, the herbal formulation increased estimated glomerular filtration rate and decreased serum creatinine levels, unlike the control group.
Mechanistic studies revealed the herbal therapy reduces inflammatory mediators CX3CL1 (search) and MCP-1 (search), targeting inflammation-driven kidney injury through specific cell populations.
Researchers from Guang'anmen Hospital (search) of the China Academy of Chinese Medical Sciences have demonstrated that a traditional Chinese herbal formula (search) can significantly improve kidney function in patients with diabetic kidney disease (search), outperforming standard therapy in key functional measures. The multicenter, randomized, double-blind clinical trial, published November 14, 2025, in Precision Clinical Medicine, enrolled 120 patients with diabetic kidney disease and macroalbuminuria (search) over 24 weeks.
Clinical Trial Results Show Functional Improvement
The study compared the herbal formulation against irbesartan, an angiotensin receptor blocker that represents current first-line therapy. While both treatments achieved similar reductions in 24-hour urinary protein—a standard marker of kidney damage—patients receiving the herbal formulation experienced significantly better preservation of kidney function.
The herbal therapy group showed increased estimated glomerular filtration rate over the treatment period, while the irbesartan group experienced decline. Additionally, serum creatinine levels decreased in the herbal treatment group rather than rising, as typically occurs with disease progression. Bayesian statistical analysis supported a high probability that the herbal therapy provided meaningful renal benefits.
Mechanistic Studies Reveal Anti-Inflammatory Pathways
To understand the superior functional outcomes, researchers conducted comprehensive mechanistic investigations combining proteomics, single-cell transcriptomics, and animal models. Olink inflammation proteomic profiling identified significant reductions in circulating inflammatory mediators, particularly CX3CL1 (search) and MCP-1 (search), following herbal treatment.
Single-nucleus RNA sequencing of diabetic mouse kidneys revealed these inflammatory molecules are predominantly expressed in endothelial, mesangial, and tubular cells—key players in kidney inflammation and fibrosis. The herbal treatment suppressed their expression in specific cell populations, suggesting a cell-type-resolved anti-inflammatory effect.
Animal experiments reinforced these clinical findings. Mice receiving the herbal therapy showed improved renal biochemical markers and reduced structural damage, including less fibrosis and mesangial expansion. The combined clinical and experimental results indicate the therapy may protect kidney function by dampening inflammation-driven injury rather than acting solely through hemodynamic control.
Clinical Significance and Future Implications
"The most striking aspect of this study is the improvement in kidney function, not just stabilization," said one of the corresponding investigators. "Many existing therapies slow decline, but few demonstrate an actual increase in filtration capacity. By integrating clinical trials with molecular and single-cell analyses, we were able to link these functional benefits to specific inflammatory pathways."
Current first-line therapies, including angiotensin-converting enzyme inhibitors (search) and angiotensin receptor blockers, typically slow renal function decline but rarely achieve sustained improvement. Treatment-related adverse effects may also limit long-term use. The study highlights inflammation as a viable therapeutic target and suggests that multi-component therapies may exert synergistic effects on complex disease pathways.
If confirmed in longer and larger trials, these findings could expand treatment options for patients with diabetic kidney disease (search), particularly those who cannot tolerate standard medications or remain at high residual risk. The work provides a framework for integrating traditional medicine with modern clinical trials and omics technologies, potentially accelerating the discovery of complementary therapies aimed at preserving kidney function for millions of patients worldwide.